Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Vízkeleti L[au]:

Genetic progression of malignant melanoma. Tímár J et al. Cancer Metastasis Rev. (2016)

Breast carcinoma subtypes show different patterns of metastatic behavior. Molnár IA et al. Virchows Arch. (2017)

Altered integrin expression patterns shown by microarray in human cutaneous melanoma. Vizkeleti L et al. Melanoma Res. (2017)

Search results

Items: 25

1.

Influence of mutagenic versus non-mutagenic pre-operative chemotherapy on the immune infiltration of residual breast cancer.

Tőkés AM, Rusz O, Cserni G, Tóth E, Rubovszky G, Tőkés T, Vízkeleti L, Reiniger L, Kószó R, Kahán Z, Kulka J, Donia M, Vörös A, Szallasi Z.

Acta Oncol. 2019 Jul 4:1-9. doi: 10.1080/0284186X.2019.1633015. [Epub ahead of print]

PMID:
31271119
2.

Molecular alterations associated with acquired resistance to BRAFV600E targeted therapy in melanoma cells.

Szász I, Koroknai V, Kiss T, Vízkeleti L, Ádány R, Balázs M.

Melanoma Res. 2019 Aug;29(4):390-400. doi: 10.1097/CMR.0000000000000588.

PMID:
30741840
3.

EGFR Protein Expression of KRAS Wild-Type Colorectal Cancer: Predictive Value of the Sidedness for Efficacy of Anti-EGFR Therapy.

Uhlyarik A, Piurko V, Vizkeleti L, Pápai Z, Rásó E, Lahm E, Kiss E, Sikter M, Vachaja J, Kenessey I, Tímár J.

Pathol Oncol Res. 2019 Jan 5. doi: 10.1007/s12253-018-00572-2. [Epub ahead of print]

PMID:
30612313
4.

LAPTM4B gene copy number gain is associated with inferior response to anthracycline-based chemotherapy in hormone receptor negative breast carcinomas.

Rusz O, Papp O, Vízkeleti L, Molnár BÁ, Bende KC, Lotz G, Ács B, Kahán Z, Székely T, Báthori Á, Szundi C, Kulka J, Szállási Z, Tőkés AM.

Cancer Chemother Pharmacol. 2018 Jul;82(1):139-147. doi: 10.1007/s00280-018-3602-z. Epub 2018 May 16.

PMID:
29770955
5.

Altered integrin expression patterns shown by microarray in human cutaneous melanoma.

Vizkeleti L, Kiss T, Koroknai V, Ecsedi S, Papp O, Szasz I, Adany R, Balazs M.

Melanoma Res. 2017 Jun;27(3):180-188. doi: 10.1097/CMR.0000000000000322.

PMID:
28234767
6.

Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.

Ács B, Zámbó V, Vízkeleti L, Szász AM, Madaras L, Szentmártoni G, Tőkés T, Molnár BÁ, Molnár IA, Vári-Kakas S, Kulka J, Tőkés AM.

Diagn Pathol. 2017 Feb 21;12(1):20. doi: 10.1186/s13000-017-0608-5.

7.

Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis.

Téglási V, Reiniger L, Fábián K, Pipek O, Csala I, Bagó AG, Várallyai P, Vízkeleti L, Rojkó L, Tímár J, Döme B, Szállási Z, Swanton C, Moldvay J.

Neuro Oncol. 2017 Aug 1;19(8):1058-1067. doi: 10.1093/neuonc/now309.

8.

Breast carcinoma subtypes show different patterns of metastatic behavior.

Molnár IA, Molnár BÁ, Vízkeleti L, Fekete K, Tamás J, Deák P, Szundi C, Székely B, Moldvay J, Vári-Kakas S, Szász MA, Ács B, Kulka J, Tőkés AM.

Virchows Arch. 2017 Mar;470(3):275-283. doi: 10.1007/s00428-017-2065-7. Epub 2017 Jan 19.

PMID:
28101678
9.

Genetic progression of malignant melanoma.

Tímár J, Vizkeleti L, Doma V, Barbai T, Rásó E.

Cancer Metastasis Rev. 2016 Mar;35(1):93-107. doi: 10.1007/s10555-016-9613-5. Review.

PMID:
26970965
10.

[Melanoma research in Hungary: promising results in a previously orphan tumor].

Balázs M, Vízkeleti L, Ecsedi S, Ádány R, Rásó E, Hegedûs B, Ladányi A, Tóvári J, Tímár J.

Magy Onkol. 2015 Dec;59(4):275-81. Epub 2015 Oct 25. Hungarian.

11.

Genomic profiling of invasive melanoma cell lines by array comparative genomic hybridization.

Koroknai V, Ecsedi S, Vízkeleti L, Kiss T, Szász I, Lukács A, Papp O, Ádány R, Balázs M.

Melanoma Res. 2016 Apr;26(2):100-7. doi: 10.1097/CMR.0000000000000227.

PMID:
26656572
12.

[Biological role and prognostic significance of genetic alterations in human malignant melanomas].

Vízkeleti L.

Magy Onkol. 2015 Sep;59(3):268-72. Epub 2015 Feb 20. Hungarian.

13.

The role of osteopontin expression in melanoma progression.

Kiss T, Ecsedi S, Vizkeleti L, Koroknai V, Emri G, Kovács N, Adany R, Balazs M.

Tumour Biol. 2015 Sep;36(10):7841-7. doi: 10.1007/s13277-015-3495-y. Epub 2015 May 7.

PMID:
25944164
14.

The strong in vivo anti-tumor effect of the UIC2 monoclonal antibody is the combined result of Pgp inhibition and antibody dependent cell-mediated cytotoxicity.

Szalóki G, Krasznai ZT, Tóth Á, Vízkeleti L, Szöllősi AG, Trencsényi G, Lajtos I, Juhász I, Krasznai Z, Márián T, Balázs M, Szabó G, Goda K.

PLoS One. 2014 Sep 19;9(9):e107875. doi: 10.1371/journal.pone.0107875. eCollection 2014.

15.

Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes.

Mezey G, Treszl A, Schally AV, Block NL, Vízkeleti L, Juhász A, Klekner A, Nagy J, Balázs M, Halmos G, Bognár L.

J Cancer Res Clin Oncol. 2014 Oct;140(10):1641-9. doi: 10.1007/s00432-014-1716-1. Epub 2014 Jun 1.

PMID:
24878932
16.

DNA methylation characteristics of primary melanomas with distinct biological behaviour.

Ecsedi S, Hernandez-Vargas H, Lima SC, Vizkeleti L, Toth R, Lazar V, Koroknai V, Kiss T, Emri G, Herceg Z, Adany R, Balazs M.

PLoS One. 2014 May 15;9(5):e96612. doi: 10.1371/journal.pone.0096612. eCollection 2014.

17.

Integrative genomics identifies gene signature associated with melanoma ulceration.

Rakosy Z, Ecsedi S, Toth R, Vizkeleti L, Hernandez-Vargas H, Lazar V, Emri G, Szatmari I, Herceg Z, Adany R, Balazs M.

PLoS One. 2013;8(1):e54958. doi: 10.1371/journal.pone.0054958. Epub 2013 Jan 30. Erratum in: PLoS One. 2013;8(4). doi:10.1371/annotation/27b2c2c3-3b09-4c0c-9e20-8dc0226404f3. Herandez-Vargas, Hector [corrected to Hernandez-Vargas, Hector].

18.

The role of CCND1 alterations during the progression of cutaneous malignant melanoma.

Vízkeleti L, Ecsedi S, Rákosy Z, Orosz A, Lázár V, Emri G, Koroknai V, Kiss T, Ádány R, Balázs M.

Tumour Biol. 2012 Dec;33(6):2189-99. doi: 10.1007/s13277-012-0480-6. Epub 2012 Sep 23.

PMID:
23001925
19.

Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.

Lázár V, Ecsedi S, Vízkeleti L, Rákosy Z, Boross G, Szappanos B, Bégány A, Emri G, Adány R, Balázs M.

Melanoma Res. 2012 Jun;22(3):202-14. doi: 10.1097/CMR.0b013e328352dbc8.

PMID:
22456166
20.

Prognostic relevance of the expressions of CAV1 and TES genes on 7q31 in melanoma.

Vizkeleti L, Ecsedi S, Rakosy Z, Begany A, Emri G, Toth R, Orosz A, Szollosi AG, Mehes G, Adany R, Balazs M.

Front Biosci (Elite Ed). 2012 Jan 1;4:1802-12.

PMID:
22201996
21.

Combined GM-CSF treatment and M-CSF inhibition of tumor-associated macrophages induces dendritic cell-like signaling in vitro.

Kitoh Y, Saio M, Gotoh N, Umemura N, Nonaka K, Bai J, Vizkeleti L, Torocsik D, Balazs M, Adany R, Takami T.

Int J Oncol. 2011 May;38(5):1409-19. doi: 10.3892/ijo.2011.960. Epub 2011 Mar 3.

PMID:
21373754
22.

Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma.

Lázár V, Ecsedi S, Szöllosi AG, Tóth R, Vízkeleti L, Rákosy Z, Bégány A, Adány R, Balázs M.

Mod Pathol. 2009 Oct;22(10):1367-78. doi: 10.1038/modpathol.2009.109. Epub 2009 Jul 24.

23.

Chromosomal imbalances are associated with increased proliferation and might contribute to bone destruction in cholesteatoma.

Ecsedi S, Rákosy Z, Vízkeleti L, Juhász A, Sziklai I, Adány R, Balázs M.

Otolaryngol Head Neck Surg. 2008 Nov;139(5):635-40. doi: 10.1016/j.otohns.2008.07.019.

PMID:
18984256
24.

Characterization of 9p21 copy number alterations in human melanoma by fluorescence in situ hybridization.

Rákosy Z, Vízkeleti L, Ecsedi S, Bégány A, Emri G, Adány R, Balázs M.

Cancer Genet Cytogenet. 2008 Apr 15;182(2):116-21. doi: 10.1016/j.cancergencyto.2008.01.008.

PMID:
18406873
25.

EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis.

Rákosy Z, Vízkeleti L, Ecsedi S, Vokó Z, Bégány A, Barok M, Krekk Z, Gallai M, Szentirmay Z, Adány R, Balázs M.

Int J Cancer. 2007 Oct 15;121(8):1729-37.

Supplemental Content

Loading ...
Support Center